198 related articles for article (PubMed ID: 27910856)
1. Acquired resistance of pancreatic cancer cells to cisplatin is multifactorial with cell context-dependent involvement of resistance genes.
Mezencev R; Matyunina LV; Wagner GT; McDonald JF
Cancer Gene Ther; 2016 Dec; 23(12):446-453. PubMed ID: 27910856
[TBL] [Abstract][Full Text] [Related]
2. Evidence for the role of microRNA 374b in acquired cisplatin resistance in pancreatic cancer cells.
Schreiber R; Mezencev R; Matyunina LV; McDonald JF
Cancer Gene Ther; 2016 Aug; 23(8):241-5. PubMed ID: 27229158
[TBL] [Abstract][Full Text] [Related]
3. MiR-223 regulates CDDP resistance in pancreatic cancer via targeting FoxO3a.
Huang R; Song X; Wang CM
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7892-7898. PubMed ID: 31599414
[TBL] [Abstract][Full Text] [Related]
4. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.
Arumugam T; Ramachandran V; Fournier KF; Wang H; Marquis L; Abbruzzese JL; Gallick GE; Logsdon CD; McConkey DJ; Choi W
Cancer Res; 2009 Jul; 69(14):5820-8. PubMed ID: 19584296
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome Remodeling in Gradual Development of Inverse Resistance between Paclitaxel and Cisplatin in Ovarian Cancer Cells.
Szenajch J; Szabelska-Beręsewicz A; Świercz A; Zyprych-Walczak J; Siatkowski I; Góralski M; Synowiec A; Handschuh L
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287223
[TBL] [Abstract][Full Text] [Related]
6. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
[TBL] [Abstract][Full Text] [Related]
7. An integrated epigenome and transcriptome analysis identifies PAX2 as a master regulator of drug resistance in high grade pancreatic ductal adenocarcinoma.
Aier I; Semwal R; Dhara A; Sen N; Varadwaj PK
PLoS One; 2019; 14(10):e0223554. PubMed ID: 31622355
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer.
Wang Z; Qin J; Zhao J; Li J; Li D; Popp M; Popp F; Alakus H; Kong B; Dong Q; Nelson PJ; Zhao Y; Bruns CJ
Theranostics; 2020; 10(16):7178-7192. PubMed ID: 32641986
[TBL] [Abstract][Full Text] [Related]
10. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
11. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
Liu F; Gore AJ; Wilson JL; Korc M
PLoS One; 2014; 9(1):e84982. PubMed ID: 24409315
[TBL] [Abstract][Full Text] [Related]
12. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer.
Noma B; Sasaki T; Fujimoto Y; Serikawa M; Kobayashi K; Inoue M; Itsuki H; Kamigaki M; Minami T; Chayama K
Int J Oncol; 2008 Dec; 33(6):1187-94. PubMed ID: 19020751
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line.
Biliran H; Wang Y; Banerjee S; Xu H; Heng H; Thakur A; Bollig A; Sarkar FH; Liao JD
Clin Cancer Res; 2005 Aug; 11(16):6075-86. PubMed ID: 16115953
[TBL] [Abstract][Full Text] [Related]
14. Transcriptome profiling of cervical cancer cells acquired resistance to cisplatin by deep sequencing.
Wang Y; Liu L; Chen Z
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):2820-2829. PubMed ID: 31293179
[TBL] [Abstract][Full Text] [Related]
15. RNF138 confers cisplatin resistance in gastric cancer cells via activating Chk1 signaling pathway.
Lu Y; Han D; Liu W; Huang R; Ou J; Chen X; Zhang X; Wang X; Li S; Wang L; Liu C; Miao S; Wang L; Ma C; Song W
Cancer Biol Ther; 2018; 19(12):1128-1138. PubMed ID: 30260263
[TBL] [Abstract][Full Text] [Related]
16. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
[TBL] [Abstract][Full Text] [Related]
17. Differences in gene expression profiles and carcinogenesis pathways involved in cisplatin resistance of four types of cancer.
Yang Y; Li H; Hou S; Hu B; Liu J; Wang J
Oncol Rep; 2013 Aug; 30(2):596-614. PubMed ID: 23733047
[TBL] [Abstract][Full Text] [Related]
18. Research of the mechanism on miRNA193 in exosomes promotes cisplatin resistance in esophageal cancer cells.
Shi S; Huang X; Ma X; Zhu X; Zhang Q
PLoS One; 2020; 15(5):e0225290. PubMed ID: 32369495
[TBL] [Abstract][Full Text] [Related]
19. [A novel chemo-resistant gene MSX2 discovered by establishment of two pancreatic cancer drug resistant cell lines JF305/CDDP and PANC-1/GEM].
Yuan W; Sui CG; Ma X; Ma J
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):330-334. PubMed ID: 29860758
[No Abstract] [Full Text] [Related]
20. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
